when his patients ask how long they’ll be at the hospital with a procedure like this, he tries to manage their expectations..
stephen silberstein, md, director, jefferson university headache center....eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention...he said: "our research shows that people, on average, believe that only 34 per cent of protection claims are paid out by insurance companies.. follow dailymail
he said: "our research shows that people, on average, believe that only 34 per cent of protection claims are paid out by insurance companies..